Sign inJoin waitlistJoin the waitlist

Jerald Radich

Molecular Oncology Director · University of Washington School of Medicine

Credentials: · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

University of Washington-Seattle Campus
1986–1988
Internal Medicine
University of Washington School of Medicine
1983–1986
MS, Epidemiology, School of Public Health, Harvard University
University of California, Davis, School of Medicine
1979–1983

Research

Massively parallel digital transcriptional profiling of single cells
Nature Communications · 2017 · 5,509 citations
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
New England Journal of Medicine · 2006 · 2,720 citations
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations

Frederick Appelbaum
66 papers
Derek Stirewalt
46 papers · 1 as a fellow
Jorge Cortes
36 papers
Soheil Meshinchi
36 papers · 5 as a fellow
Hagop Kantarjian
31 papers
Vivian Oehler
29 papers · 1 as a fellow
TC
Thomas Chauncey
28 papers
Cheryl Willman
27 papers
Michael Deininger
26 papers
Richard Larson
26 papers
Harry Erba
25 papers
Rainer Storb
24 papers

Grants

ITSC for Leukemia: Novel Molecular Strategies for NCTN "Individualized" Therapies
National Cancer Institute · UG1
PI · $2M · University of Cincinnati
2019–2025
Understanding and Predicting Relapse in Acute Myeloid Leukemia
National Cancer Institute · R01
Contact PI · $3.9M · Fred Hutchinson Cancer Center
2013–2024
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia
National Cancer Institute · R01
PI · $2.2M · Fred Hutchinson Cancer Center
2018–2023
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia Using Duplex Sequencing
National Cancer Institute · R44
PI · $2.5M · Twinstrand Biosciences, Inc.
2018–2022

Clinical trials

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029